National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Romiplostim (Nplate®) is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.

Commenced Completed Outcome
02/04/2015 27/05/2015 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.

Re-submission

Romiplostim is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

The Applicant is seeking reimbursement under the High Tech Drug Arrangements.

NCPE Assessment Process Complete
Rapid review commissioned 18/06/2019
Rapid review completed 18/07/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of romiplostim compared with the current standard of care.